StockIQpro
NYSE:ARMP

Armata Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Armata Pharmaceuticals, Inc. reported net income of −$173.8M in fiscal 2025. Free cash flow was −$26.3M, and the diluted share count fell 38.6%.Summary generated from Armata Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 25, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$26.3M
FCF marginn/a
Share count change−38.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−24−37−41−42−37
Net income−23−37−69−19−174
Free cash flow−25−35−56−39−26

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)